Showing results (171-180 of 221) with videos related to

Sort By:
Pageof 23
Gynecologic Oncology|March 16, 2021
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundationBradley J Monk, Robert L Coleman, Thomas J Herzog, et al.
Gynecologic Oncology|January 22, 2022
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation studyBrian M Slomovitz, Virginia L Filiaci, Joan L Walker, et al.
Cancer Research Communications|August 5, 2022
The vaginal microbiome is associated with endometrial cancer grade and histologyHesamedin Hakimjavadi, Sophia H George, Michael Taub, et al.
Gynecologic Oncology|January 11, 2015
Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional studyHaider Mahdi, Peter G Rose, Mohammed A Elshaikh, et al.
Gynecologic Oncology|February 3, 2015
Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution studyHaider Mahdi, Mohamed A Elshaikh, Robert DeBenardo, et al.
Nature Communications|April 26, 2023
Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5LChristopher J LaFargue, Paola Amero, Kyunghee Noh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO TrialJung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Future Oncology (London, England)|August 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancerDavid M O'Malley, Leslie M Randall, Camille Gunderson Jackson, et al.
Oncoimmunology|April 17, 2023
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppressionPaul G Pavicic, Patricia A Rayman, Shadi Swaidani, et al.
JNCI Cancer Spectrum|June 30, 2020
Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort StudyStefan Klek, Brandie Heald, Alex Milinovich, et al.
Pageof 23